ATE532793T1 - Verfahren zur herstellung von molekülen mit verminderter immunogenität - Google Patents

Verfahren zur herstellung von molekülen mit verminderter immunogenität

Info

Publication number
ATE532793T1
ATE532793T1 AT04809479T AT04809479T ATE532793T1 AT E532793 T1 ATE532793 T1 AT E532793T1 AT 04809479 T AT04809479 T AT 04809479T AT 04809479 T AT04809479 T AT 04809479T AT E532793 T1 ATE532793 T1 AT E532793T1
Authority
AT
Austria
Prior art keywords
protein
peptide
reduced immunogenicity
producing molecules
cross
Prior art date
Application number
AT04809479T
Other languages
English (en)
Inventor
Christopher Marshall
Original Assignee
Avatar Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avatar Biotechnologies Inc filed Critical Avatar Biotechnologies Inc
Application granted granted Critical
Publication of ATE532793T1 publication Critical patent/ATE532793T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04809479T 2003-07-03 2004-07-06 Verfahren zur herstellung von molekülen mit verminderter immunogenität ATE532793T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48488003P 2003-07-03 2003-07-03
PCT/US2004/021859 WO2005051975A2 (en) 2003-07-03 2004-07-06 Methods for obtaining molecules with reduced immunogenicity

Publications (1)

Publication Number Publication Date
ATE532793T1 true ATE532793T1 (de) 2011-11-15

Family

ID=34632731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04809479T ATE532793T1 (de) 2003-07-03 2004-07-06 Verfahren zur herstellung von molekülen mit verminderter immunogenität

Country Status (7)

Country Link
US (1) US20050054572A1 (de)
EP (1) EP1641813B1 (de)
JP (1) JP5009614B2 (de)
AT (1) ATE532793T1 (de)
AU (2) AU2004293371A1 (de)
CA (1) CA2530756C (de)
WO (1) WO2005051975A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090060450A (ko) 2006-10-04 2009-06-12 얀센 파마슈티카 엔.브이. 불활성화 인공 항원 제시 세포의 제조 및 세포 치료법에서 이들의 용도
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20130302366A1 (en) * 2012-05-09 2013-11-14 Christopher Marshall Conformationally Specific Viral Immunogens
EP3024483B1 (de) 2013-07-25 2020-01-15 Calder Biosciences Inc. Konformationsstabilisierte rsv-f-präfusionsproteine
ES2832733T3 (es) 2013-08-03 2021-06-11 Calder Biosciences Inc Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe
WO2019032480A1 (en) 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3983537A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
GB2339430A (en) * 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
AU1207301A (en) * 1999-10-15 2001-04-30 Avatar Medical, Llc Stabilized proteins
CA2440474A1 (en) * 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment

Also Published As

Publication number Publication date
JP5009614B2 (ja) 2012-08-22
EP1641813A4 (de) 2006-08-30
JP2007537133A (ja) 2007-12-20
CA2530756C (en) 2012-10-16
US20050054572A1 (en) 2005-03-10
WO2005051975A2 (en) 2005-06-09
CA2530756A1 (en) 2005-06-09
EP1641813B1 (de) 2011-11-09
AU2004293371A1 (en) 2005-06-09
AU2011200649A1 (en) 2011-03-10
WO2005051975A3 (en) 2005-12-29
EP1641813A2 (de) 2006-04-05

Similar Documents

Publication Publication Date Title
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE532793T1 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität
EP1453850A4 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
ATE258807T1 (de) Verfahren zur markierung von biopolymeren mit isotopen
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
EP1504111A4 (de) Peptide mit unnatürlichen aminosäureresten enthaltende nukleinsäure-peptid-display-bibliotheken und verfahren zur herstellung davon
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE334998T1 (de) Verfahren zur herstellung cyclischer peptide
DE602005021485D1 (de) Verfahren und zusammensetzungen mit molkeproteinisolaten
DE602005022387D1 (de) Verfahren zur Herstellung von Dipeptiden
DE60125218D1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE495247T1 (de) Chromoprotein und fluoroproteine
WO2003050283A3 (en) A structure for presenting desired peptide sequences
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
DE60027932D1 (de) Verfahren zur herstellung von proteinhydrolysaten
WO2004108749A3 (en) Binding peptides: methods for their generation and use
DE69734586D1 (de) Retinoid-metabolisierendes protein
ATE481641T1 (de) Verfahren zur fixierung eines proteins auf einem pyrrolpolymerisat, und dessen verwendung zur herstellung eines sensors
DE602004032042D1 (de) Bibliotheken rekombinanter chimärischer proteine
ATE171711T1 (de) Cyclohexapeptide und deren mischungen, verfahren zur herstellung sowie deren verwendung